Finance
Pfizer to Sell Entire Haleon Stake
Published by Global Banking & Finance Review®
Posted on March 18, 2025
1 min readLast updated: January 24, 2026
Add as preferred source on GoogleGlobal Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on March 18, 2025
1 min readLast updated: January 24, 2026
Add as preferred source on GooglePfizer will sell its remaining 7.3% stake in Haleon, allowing BlackRock to become the largest shareholder. Haleon anticipates revenue growth in late 2025.
(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday.
Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK and Pfizer's consumer healthcare businesses in 2019, and spun off in 2022.
Under the deal, the Sensodyne maker has agreed to buy back shares worth $220 million from Pfizer, currently its largest shareholder.
GSK, which initially owned nearly 13% of the firm, sold its entire stake in May 2024.
Following Pfizer's disposal, BlackRock Investment Management (UK) Ltd, a unit of BlackRock, will become Haleon's largest shareholder with over a 5% stake, according to data compiled by LSEG.
Haleon in February said its 2025 revenue and profit growth weighted to the second half of the year.
(Reporting by Prerna Bedi in Bengaluru; Editing by Alan Barona)
The article discusses Pfizer's decision to sell its remaining stake in Haleon, a consumer healthcare group.
Following Pfizer's sale, BlackRock Investment Management will become Haleon's largest shareholder.
Haleon was created from a merger between GSK and Pfizer's consumer healthcare businesses in 2019.
Explore more articles in the Finance category
